Scribe Therapeutics Inc. (Nasdaq: SCTX), a clinical-stage biotechnology firm headquartered in Alameda, California, finalized its initial public offering on July 27, 2026, raising approximately $155.51 million in aggregate gross proceeds before underwriting discounts and commissions.
The company sold a total of 9,867,000 shares of common stock at a price of $15.00 per share. That figure includes 1,287,000 additional shares that were issued following the full exercise of the underwriters' option.
Scribe's shares began trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol "SCTX." The firm's registration statement with the U.S. Securities and Exchange Commission became effective on July 23, 2026.
Concurrent with the public offering, Scribe completed a private placement of 500,000 shares to Sanofi at the same IPO price of $15.00 per share. The company notes that those privately placed shares were not registered under the Securities Act of 1933.
Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities acted as joint book-running managers for the offering.
Context and mechanics
The proceeds reported are stated on a gross basis, before deducting underwriting discounts and commissions. The offering structure included an option for underwriters to purchase additional shares, which was exercised in full and resulted in the issuance of 1,287,000 extra shares that are reflected in the total shares sold.
The company also executed a simultaneous private placement to Sanofi of 500,000 shares at the IPO price. Those shares were issued outside the registration under the Securities Act of 1933, a detail noted in the company statement.
Deal parties
Four firms served as joint book-running managers for the transaction: Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities.
Regulatory step
Scribe's registration statement became effective with the U.S. Securities and Exchange Commission on July 23, 2026, clearing the way for the subsequent public trading that commenced on July 24, 2026 and for the offering to close on July 27, 2026.
Note on sources
The information presented here is based on a press release statement issued by Scribe Therapeutics.